Published in Lab Law Weekly, June 1st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at GlaxoSmithKline plc.
Report 1: GlaxoSmithKline (NYSE:GSK) has confirmed that its new treatment TYKERB(R) (lapatinib) will be available through Commitment to Access, the company's program that provides low income patients with access to GSK products used in an outpatient setting in the United States.
As part of Commitment to Access, patients who have been prescribed TYKERB and have no insurance coverage may be eligible to receive TYKERB free of charge if they live in one of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.